Anti-ischemic effects of celiprolol in patients with exercise-induced angina pectoris

Douard, H.; Koch, Michel; Laporte, Thierry; Abella, M.L.; Provendier, O; Jp, Broustet

doi:10.1016/0167-5273(89)90163-0

Cited by 6 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrasting decreases in cardiac output or cardiac index were reported after treatment with aten-0101[20.2IJ or metoprolo\J14] In patients with hypertension and angina, intravenous celiprolol caused significant increases in cardiac index, left ventricular ejection fraction, systolic ejection rate and circumferential fibre shortening, compared with metoproloi. [61] The product of heart rate and SBP correlates with myocardial oxygen consumption. [3I] A transient improvement in left ventricular performance (shown by pre-ejection period/left ventricular ejection time) occurred in 7 healthy volunteers during administration of celiprolol400 mg/day.…”

Section: Cardiac and Haemodynamic Effectsmentioning

confidence: 99%

Celiprolol

Dunn¹,

Spencer²

1995

Drugs & Aging

View full text Add to dashboard Cite

Celiprolol is a beta 1-selective adrenoceptor antagonist (beta-blocker) which acts as a weak agonist at beta 2-adrenoceptors. The drug demonstrates vasodilator properties and does not depress heart rate to the same extent as propranolol, atenolol or metoprolol. Celiprolol has shown equivalent antihypertensive efficacy to other beta-blockers, notably propranolol, atenolol, metoprolol and pindolol, in patients aged 18 to 75 years with mild to moderate essential hypertension. The drug has also shown similar antihypertensive efficacy to the angiotensin converting enzyme inhibitor enalapril and to combination diuretic therapy with hydrochlorothiazide and amiloride. Celiprolol was equally effective in adult patients of all ages, although no data are available for patients aged over 75 years. Data from a small number of clinical trials indicate celiprolol to be as effective as both propranolol and atenolol in improving work capacity and reducing the frequency of anginal attacks in patients with stable effort angina. However, the drug has not yet been evaluated in postmyocardial infarction patients. Celiprolol offers advantages over other beta-blockers, including reduction of peripheral vascular resistance and maintenance of resting heart rate, cardiac output and renal perfusion. The drug is also associated with improvements in plasma lipid profiles and does not appear to adversely affect carbohydrate metabolism or lung function, although its use in patients with reversible obstructive pulmonary disease is not recommended. Celiprolol is therefore a highly cardioselective beta-blocker with ancillary characteristics which are potentially useful in patients with hypertension and angina complicated by other conditions commonly associated with advanced age. These include impaired glucose tolerance or diabetes mellitus, peripheral vascular disease and hyperlipidaemia. The drug may also be preferred to other beta-blockers in patients in whom a reduction in heart rate would be particularly undesirable. Further long term (> 12 months) clinical trials and pharmacoeconomic data are now required to confirm the clinical relevance of the pharmacodynamic advantages of celiprolol therapy.

show abstract

Section: Cardiac and Haemodynamic Effectsmentioning

confidence: 99%

Celiprolol

Dunn¹,

Spencer²

1995

Drugs & Aging

View full text Add to dashboard Cite

show abstract

A Pressor Effect of Nonselective Beta-Blockers in Unstable Angina Pectoris

Cleophas¹

1995

Beta-Blockers in Hypertension and Angina Pectoris

View full text Add to dashboard Cite

Celiprolol and propranolol for unstable angina pectoris

Cleophas¹,

Leven²,

Kauw³

et al. 1995

Clin Pharmacol Ther

View full text Add to dashboard Cite

Both celiprolol and propranolol largely reduce angina pectoris frequency in unstable angina pectoris. Celiprolol contributes to nearly complete relief in three times as many patients as propranolol; after adjustment for double product, it did so in eight times as many patients. The similar effects of the two compounds on the double product, and the essentially different effects on peripheral flow, support the theory that celiprolol exerts its beneficial effect to a large extent through its vasodilatory property.

show abstract

Anti-ischemic effects of celiprolol in patients with exercise-induced angina pectoris

Cited by 6 publications

References 6 publications

Celiprolol

Celiprolol

A Pressor Effect of Nonselective Beta-Blockers in Unstable Angina Pectoris

Celiprolol and propranolol for unstable angina pectoris

Contact Info

Product

Resources

About